First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Outlook Therapeutics, Inc.

    OTLK · 3 developments mapped · last assessed 2026-08-14

    Market Ontology has mapped 3 macro, policy, and market developments to Outlook Therapeutics, Inc. since 2026-08-13. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for OTLK yet, so no modelled value is shown. The OTLK valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run OTLK on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for OTLK. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Main threat

      Outlook Therapeutics, Inc. Follow-On — $51M

      Dilution from new share issuance, potential downward pressure on share price due to increased supply, and uncertainty regarding the use of proceeds relative to the dilution.

      · Moves shares outstanding, cost of equity (due to increased risk perception), future cash flow per share

    • Open question

      Outlook Therapeutics, Inc. Follow-On — $55M

      Direct dilution from equity offering; improved liquidity and funding for operations/development; potential downward pressure on stock price due to increased supply and offering price.

      · Moves future cash flow discount rate (wacc), per share metrics (eps, fcf/share), probability of successful drug development/commercialization

    What changed, by assumption

    Shares outstanding
    • 2026-08-14Outlook Therapeutics, Inc. Follow-On — $51M
    Equity value per share
    • 2026-08-13Outlook Therapeutics Follow-On — $55M
    Future cash flow discount rate (wacc)
    • 2026-08-13Outlook Therapeutics, Inc. Follow-On — $55M

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-13Share countBullishThe issuance of common stock and warrants in a $55M public offering will increase the total shares outstanding.0.90
    2026-08-13Share countBullishPublic offering of common stock and warrants will increase the total shares outstanding upon closing and exercise.0.90
    2026-08-13Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-13Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-06-16RevenueBullishFDA acceptance of BLA resubmission for ONS-5010 with a PDUFA date in July 2026 moves the company closer to commercialization and first-ever revenue from this product.0.90

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-14Outlook Therapeutics, Inc. Follow-On — $51MBearish1-3m0.80
    2026-08-13Outlook Therapeutics, Inc. Follow-On — $55Mmixed1-3m0.70
    2026-08-13Outlook Therapeutics Follow-On — $55MBearish1-3m0.80